These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 18085368

  • 1. Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case.
    Utsunomiya T, Okamoto M, Yano S, Kameyama T, Matsuyama A, Kuma S, Yamamoto M, Fujiwara M, Ishida T.
    Surg Today; 2008; 38(1):65-7. PubMed ID: 18085368
    [Abstract] [Full Text] [Related]

  • 2. Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment.
    Koyama T, Nimura H, Kobayashi K, Marushima H, Odaira H, Kashimura H, Mitsumori N, Yanaga K.
    Gastric Cancer; 2006; 9(3):235-9. PubMed ID: 16952044
    [Abstract] [Full Text] [Related]

  • 3. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
    Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP, Besmer P, Antonescu CR.
    Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
    [Abstract] [Full Text] [Related]

  • 4. Predicting the antitumor effects of STI571 by analysis of c-kit gene mutations in gastrointestinal stromal tumors of the stomach: Report of a case.
    Tsuneoka N, Kuroki T, Haraguchi M, Furui J.
    Surg Today; 2006 Oct; 36(11):989-93. PubMed ID: 17072721
    [Abstract] [Full Text] [Related]

  • 5. Molecular research directions in the management of gastrointestinal stromal tumors.
    Tarn C, Godwin AK.
    Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
    [Abstract] [Full Text] [Related]

  • 6. Emergence of imatinib resistance associated with downregulation of c-kit expression in recurrent gastrointestinal stromal tumor (GIST): optimal timing of resection.
    Dudeja V, Armstrong LH, Gupta P, Ansel H, Askari S, Al-Refaie WB.
    J Gastrointest Surg; 2010 Mar; 14(3):557-61. PubMed ID: 20033343
    [Abstract] [Full Text] [Related]

  • 7. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.
    Lim KH, Huang MJ, Chen LT, Wang TE, Liu CL, Chang CS, Liu MC, Hsieh RK, Tzen CY.
    Med Oncol; 2008 Mar; 25(2):207-13. PubMed ID: 18488160
    [Abstract] [Full Text] [Related]

  • 8. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
    Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, Van Oosterom A, Marynen P.
    Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
    [Abstract] [Full Text] [Related]

  • 9. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
    Hong JL, Li J, Li J, Shen L.
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
    [Abstract] [Full Text] [Related]

  • 10. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
    Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD.
    J Clin Oncol; 2008 Nov 20; 26(33):5352-9. PubMed ID: 18955458
    [Abstract] [Full Text] [Related]

  • 11. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.
    Wang CM, Huang K, Zhou Y, Du CY, Ye YW, Fu H, Zhou XY, Shi YQ.
    J Cancer Res Clin Oncol; 2010 Jul 20; 136(7):1065-71. PubMed ID: 20043176
    [Abstract] [Full Text] [Related]

  • 12. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
    Kikuchi H, Setoguchi T, Miyazaki S, Yamamoto M, Ohta M, Kamiya K, Sakaguchi T, Konno H.
    Int J Clin Oncol; 2011 Dec 20; 16(6):741-5. PubMed ID: 21394667
    [Abstract] [Full Text] [Related]

  • 13. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
    Lasota J, Miettinen M.
    Semin Diagn Pathol; 2006 May 20; 23(2):91-102. PubMed ID: 17193822
    [Abstract] [Full Text] [Related]

  • 14. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.
    Yeh CN, Chen TW, Wu TJ, Hsueh S, Jan YY.
    World J Gastroenterol; 2006 Jun 21; 12(23):3760-5. PubMed ID: 16773696
    [Abstract] [Full Text] [Related]

  • 15. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A, Boglione A.
    Recenti Prog Med; 2015 Jan 21; 106(1):17-22. PubMed ID: 25621775
    [Abstract] [Full Text] [Related]

  • 16. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF.
    Ann Surg Oncol; 2007 Mar 21; 14(3):1123-8. PubMed ID: 17195905
    [Abstract] [Full Text] [Related]

  • 17. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
    Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, Kim WH, Im SA, Bang YJ, Park SH, Lee JH, Chung IJ, Bae HI, Kim JG, Lee KH, Song HS, Kwon HC, Baek JH, Shin DB, Lee KE, Kang YK.
    Acta Oncol; 2012 Apr 21; 51(4):528-36. PubMed ID: 22150077
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Multidisciplinary treatment of gastrointestinal stromal tumors.
    Kingham TP, DeMatteo RP.
    Surg Clin North Am; 2009 Feb 21; 89(1):217-33, x. PubMed ID: 19186237
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.